2-Methoxyestradiol reduces monocyte adhesion to aortic endothelial cells in ovariectomized rats

Endocrine Journal

Volumn 54, Issue 6, 2007, Pages 1027-1031

  Kurokawa, Atsuko ^a   Azuma, Kosuke ^a   Mita, Tomoya ^a   Toyofuku, Yukiko ^a   Fujitani, Yoshio ^a   Hirose, Takahisa ^a   Iwabuchi, Kazuhisa ^a   Ogawa, Hideoki ^a   Takeda, Satoru ^a   Kawamori, Ryuzo ^a   Watada, Hirotaka ^a,b  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease; Estrogen; Hormone replacement therapy; Menopause

Indexed keywords

2 METHOXYESTRADIOL; ESTRADIOL; ESTROGEN RECEPTOR; GLUCOSE; LIPID; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; LIPID BLOOD LEVEL; LOW DRUG DOSE; MONOCYTE; NONHUMAN; OVARIECTOMY; RAT; SLOW DRUG RELEASE; SPRAGUE DAWLEY RAT; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; AREA UNDER CURVE; ATHEROSCLEROSIS; BLOOD GLUCOSE; BLOOD PRESSURE; CELL ADHESION; CHOLESTEROL; ENDOTHELIAL CELLS; ESTRADIOL; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; MONOCYTES; OVARIECTOMY; POSTMENOPAUSE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 40449105605     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07E-034     Document Type: Article

References (25)

1. Kannel WB, Hjortland MC, McNamara PM, Gordon T (1976) Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85: 447-452.
2. Barrett-Connor E (1997) Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 95: 252-264.
3. Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265: 1861-1867.
4. Kannel WB, Abbott RD (1984) Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 311: 1144-1147.
5. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH (1987) Menopause and the risk of coronary heart disease in women. N Engl J Med 316: 1105-1110.
6. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117: 1016-1037.
7. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000) A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933-941.
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613.
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
10. Dubey RK, Imthurn B, Zacharia LC, Jackson EK (2004) Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 44: 789-795.
11. Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340: 1801-1811.
12. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR, Jr., Lubahn DB, O'Donnell TF, Jr., Korach KS, Mendelsohn ME (1997) Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 3: 545-548.
13. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME (2002) Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90: 1087-1092.
14. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK (2006) 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res 99: 266-274.
15. Tofovic SP, Salah EM, Dubey RK, Melhem MF, Jackson EK (2005) Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol 46: 25-35.
16. Tofovic SP, Salah EM, Mady HH, Jackson EK, Melhem MF (2005) Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 46: 430-437.
17. Bourghardt J, Bergstrom G, Krettek A, Sjoberg S, Boren J, Tivesten A (2007) The endogenous estradiol metabolite 2-methoxyestradiol reduces atherosclerotic lesion formation in female ApoE-deficient mice. Endocrinology 148: 4128-4132.
18. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126.
19. Azuma K, Watada H, Niihashi M, Otsuka A, Sato F, Kawasumi M, Shimada S, Tanaka Y, Kawamori R, Mitsumata M (2003) A new En face method is useful to quantitate endothelial damage in vivo. Biochem Biophys Res Commun 309: 384-390.
20. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N (2001) Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest 107: 333-340.
21. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M (2001) Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 37: 640-644.
22. Markides CS, Roy D, Liehr JG (1998) Concentration dependence of prooxidant and antioxidant properties of catecholestrogens. Arch Biochem Biophys 360: 105-112.
23. Seeger H, Mueck AO, Lippert TH (1999) Effect of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sci 65: PL167-170.
24. Liu ML, Xu X, Rang WQ, Li YJ, Song HP (2004) Influence of ovariectomy and 17beta-estradiol treatment on insulin sensitivity, lipid metabolism and post-ischemic cardiac function. Int J Cardiol 97: 485-493.
25. Dantas AP, Sandberg K (2006) Does 2-methoxyestradiol represent the new and improved hormone replacement therapy for atherosclerosis? Circ Res 99: 234-237.